Cavli Wireless Is Set to Unveil the Next Generation of LPWAN-based IoT with C42GM Smart Cellular IoT Module at Embedded World 2022, Germany.
17.6.2022 13:31:00 EEST | Business Wire | Press release
Cavli Wireless will participate in the Embedded World 2022 edition in Nuremberg, Germany, from June 21-23, 2022. The Embedded World event is the world's biggest trade fair for everything Embedded, from electronic systems, distributed intelligence, the Internet of Things, e-mobility, energy efficiency, and much more. The company will be exhibiting its IoT connectivity solutions in hall 5, booth no: 5-362.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005168/en/
Powering the next generation of LPWAN IoT with Cavli C42GM Smart Cellular IoT Module (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the new launch of the C42GM LTE CAT M1/NB1/NB2 compatible Smart Cellular IoT Module, which can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems, and more.
C42GM is a dual-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module, based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS and Sigfox radio capability that can equip OEMs to explore use cases that need the hybrid LPWAN approach. As John Mathew, Chief Technology Architect at Cavli Wireless, quoted, “the integrated eSIM coupled with pre-loaded global connectivity further cements the C42GM as the world's most powerful LPWAN-based cellular IoT module."
By virtue of the Hubble Stack Intelligence, C42GM can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT Management platform wherein a customer or a Cavli Support Engineer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
Due to Cavli’s strong operator partnerships in the EU, we have an extensive footprint across Europe for our local LTE as well LTE-M connectivity offering, which is unparalleled in the industry in terms of service quality & pricing.
Join Cavli Wireless on June 22 at 16:00 GMT and participate in the exhibitor's forum where Thomas Fesquet, Business Engagement Manager for Cavli Wireless will be unveiling C42GM for our European customers & technology partners visiting the Embedded World event. Watch this video by Cavli Wireless for more information https://www.youtube.com/watch?v=DfyRiYjpkdM
"The Embedded World 2022 event is the premier trade fair for technology companies from around the globe to present their flagship offerings," said Tarun Thomas George, Chief Operating Officer at Cavli Wireless. "We are beyond excited to be a part of this prestigious event, share the stage alongside industry heavyweights, and demonstrate to the world how Cavli Wireless is democratizing the Internet of Things."
About Cavli Wireless
Cavli Wireless designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded World Exhibition & Conference in Nuremberg offers the embedded community the opportunity to learn about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005168/en/
Contact information
Ajit Thomas, CMO, Cavli Wireless Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom